结直肠癌
医学
内科学
药品
肿瘤科
癌症
药理学
出处
期刊:Cancer Discovery
[American Association for Cancer Research]
日期:2018-11-30
卷期号:9 (1): 8-8
被引量:38
标识
DOI:10.1158/2159-8290.cd-nb2018-162
摘要
A novel anti-HER2 therapy, ZW25, may be effective and well tolerated in patients with a variety of HER2-positive cancers. In a phase I trial, patients treated with the drug-most of whom had gastroesophageal or colorectal cancer-had an objective response rate of 41% and mild side effects.
科研通智能强力驱动
Strongly Powered by AbleSci AI